To the full analysis
Encompass Health stock: growth
EHCEncompass Health reported $5.94B in revenue for fiscal 2025, up 10.5% on the prior year, up 10.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.8%
per year from 2006 to 2025, per share 5.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 10.7% | 6.7% | 6.8% |
| Revenue per share | 10.3% | 5.4% | 5.5% |
| Earnings | 14.8% | 12.0% | no data |
| Earnings per share | 14.4% | 10.8% | no data |
| Free cash flow | 8.2% | 3.0% | no data |
| Free cash flow per share | 7.8% | 1.8% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.71B | −$625M | −$219.6M |
| 2007 | $1.74B | $653.4M | $191.3M |
| 2008 | $1.83B | $252.4M | $153M |
| 2009 | $1.91B | $94.8M | $333.5M |
| 2010 | $1.86B | $899M | $260.1M |
| 2011 | $2.01B | $208.7M | $233.6M |
| 2012 | $2.13B | $185M | $251.8M |
| 2013 | $2.25B | $323.6M | $253.8M |
| 2014 | $2.37B | $222M | $257M |
| 2015 | $3.12B | $183.1M | $328.3M |
| 2016 | $3.64B | $247.6M | $402.6M |
| 2017 | $3.91B | $271.1M | $412.2M |
| 2018 | $4.28B | $292.3M | $491.9M |
| 2019 | $4.61B | $358.7M | $231.2M |
| 2020 | $3.57B | $284.2M | $296.5M |
| 2021 | $4.01B | $412.2M | $164.6M |
| 2022 | $4.35B | $271M | $121.7M |
| 2023 | $4.8B | $352M | $267.7M |
| 2024 | $5.37B | $455.7M | $360.3M |
| 2025 | $5.94B | $566.2M | $439.2M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 30 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.